JP2007533670A5 - - Google Patents

Download PDF

Info

Publication number
JP2007533670A5
JP2007533670A5 JP2007508701A JP2007508701A JP2007533670A5 JP 2007533670 A5 JP2007533670 A5 JP 2007533670A5 JP 2007508701 A JP2007508701 A JP 2007508701A JP 2007508701 A JP2007508701 A JP 2007508701A JP 2007533670 A5 JP2007533670 A5 JP 2007533670A5
Authority
JP
Japan
Prior art keywords
composition
cytarabine
daunorubicin
liposome
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007508701A
Other languages
English (en)
Japanese (ja)
Other versions
JP4972545B2 (ja
JP2007533670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/000625 external-priority patent/WO2005102359A1/en
Publication of JP2007533670A publication Critical patent/JP2007533670A/ja
Publication of JP2007533670A5 publication Critical patent/JP2007533670A5/ja
Application granted granted Critical
Publication of JP4972545B2 publication Critical patent/JP4972545B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007508701A 2004-04-22 2005-04-22 アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤 Expired - Lifetime JP4972545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
US60/565,210 2004-04-22
PCT/CA2005/000625 WO2005102359A1 (en) 2004-04-22 2005-04-22 Liposomal formulations of anthracycline agents and cytidine analogs

Publications (3)

Publication Number Publication Date
JP2007533670A JP2007533670A (ja) 2007-11-22
JP2007533670A5 true JP2007533670A5 (cg-RX-API-DMAC10.html) 2011-04-21
JP4972545B2 JP4972545B2 (ja) 2012-07-11

Family

ID=35196733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007508701A Expired - Lifetime JP4972545B2 (ja) 2004-04-22 2005-04-22 アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤

Country Status (13)

Country Link
US (2) US8022279B2 (cg-RX-API-DMAC10.html)
EP (2) EP2407169A1 (cg-RX-API-DMAC10.html)
JP (1) JP4972545B2 (cg-RX-API-DMAC10.html)
AU (1) AU2005235455B2 (cg-RX-API-DMAC10.html)
BE (1) BE2018C045I2 (cg-RX-API-DMAC10.html)
CA (1) CA2564542C (cg-RX-API-DMAC10.html)
CY (2) CY1113012T1 (cg-RX-API-DMAC10.html)
ES (1) ES2388064T3 (cg-RX-API-DMAC10.html)
FR (1) FR18C1047I2 (cg-RX-API-DMAC10.html)
IL (1) IL178779A (cg-RX-API-DMAC10.html)
NL (1) NL300960I2 (cg-RX-API-DMAC10.html)
PT (1) PT1744764E (cg-RX-API-DMAC10.html)
WO (1) WO2005102359A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2581133A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
EP1888034A2 (en) * 2005-05-26 2008-02-20 Yissum Research Development Company, of The Hebrew University of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
PT2120568T (pt) * 2007-02-16 2017-12-04 Celator Pharmaceuticals Inc Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas
US20110021517A1 (en) * 2008-02-26 2011-01-27 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
PT2768484T (pt) 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
EP2833905B1 (en) 2012-04-04 2018-05-02 Halozyme, Inc. Combination therapy with hyaluronidase and a tumor-targeted taxane
BR112014028094B1 (pt) * 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
AU2016256979B2 (en) 2015-05-04 2021-01-28 Genfit Method for preparing transmembrane pH-gradient vesicles
MA43184A (fr) * 2015-11-02 2021-04-14 Fujifilm Corp Composition liposomale et son procédé de production
BR112018009463A8 (pt) 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US20240252522A1 (en) 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
KR20230131934A (ko) * 2021-01-20 2023-09-14 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 암을 치료하기 위한 조합 치료요법 스케줄
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (cg-RX-API-DMAC10.html) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
EP1432403B1 (en) * 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1608337A2 (en) * 2003-04-02 2005-12-28 Celator Technologies Inc. Combination compositions of camptothecins and fluoropyrimidines
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Similar Documents

Publication Publication Date Title
JP7686017B2 (ja) 非結核性抗酸菌肺感染症を治療するための方法
EP2632553B1 (en) A sustained release formulation of a non-steroidal anti-inflammatory drug
KR101301653B1 (ko) 항감염제의 지속적인 방출
ES2388064T3 (es) Formulaciones liposomales de agentes de antraciclina y análogos de citidina
JP2004532186A5 (cg-RX-API-DMAC10.html)
JP2005509000A5 (cg-RX-API-DMAC10.html)
HK40086177B (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
HK40043803B (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
WO2006005415A3 (en) Use of l-carnitine and glucose for the treatment of cardiovascular diseases
HK1187291A (en) A sustained release formulation of a non-steroidal anti-inflammatory drug
HK1187291B (en) A sustained release formulation of a non-steroidal anti-inflammatory drug
HK1230985A1 (en) Methods for treating pulmonary non-tuberculous mycobacterial infections
HK1230985B (en) Methods for treating pulmonary non-tuberculous mycobacterial infections